Dana-Farber investigators reported early phase results from CAR-PRISM testing CAR-T in high-risk smoldering multiple myeloma, aiming to intercept disease before it becomes active. The dataset was presented as part of an emerging shift toward moving immunotherapy earlier along the disease continuum. The trial approach combines intensive monitoring with CAR-T deployment in a precancerous stage, with the intent to drive deep molecular responses. Reporting described complete clearance of detectable myeloma cells in all treated patients in the cohort. If replicated in larger studies, the results could influence how companies and clinicians think about endpoints and treatment goals for pre-malignant plasma cell disorders, where standard options often focus on long-term disease suppression rather than deep eradication.